Igene Financial Statements From 2010 to 2025
Igene Biotechnology financial statements provide useful quarterly and yearly information to potential Igene Biotechnology investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Igene Biotechnology financial statements helps investors assess Igene Biotechnology's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Igene Biotechnology's valuation are summarized below:Igene Biotechnology does not presently have any fundamental trends for analysis.
This module can also supplement various Igene Biotechnology Technical models . Check out the analysis of Igene Biotechnology Correlation against competitors.
Check Igene Biotechnology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Igene Biotechnology's main balance sheet or income statement drivers, such as , as well as many indicators such as . Igene financial statements analysis is a perfect complement when working with Igene Biotechnology Valuation or Volatility modules.
Igene |
Igene Biotechnology Company Current Valuation Analysis
Igene Biotechnology's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Igene Biotechnology Current Valuation | 1.1 M |
Most of Igene Biotechnology's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Igene Biotechnology is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Igene Biotechnology has a Current Valuation of 1.1 M. This is 99.99% lower than that of the Chemicals sector and 99.99% lower than that of the Materials industry. The current valuation for all United States stocks is 99.99% higher than that of the company.
Igene Biotechnology Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Igene Biotechnology's current stock value. Our valuation model uses many indicators to compare Igene Biotechnology value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Igene Biotechnology competition to find correlations between indicators driving Igene Biotechnology's intrinsic value. More Info.Igene Biotechnology is rated third overall in return on asset category among its peers. It is rated fourth overall in operating margin category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Igene Biotechnology's earnings, one of the primary drivers of an investment's value.About Igene Biotechnology Financial Statements
Igene Biotechnology stakeholders use historical fundamental indicators, such as Igene Biotechnology's revenue or net income, to determine how well the company is positioned to perform in the future. Although Igene Biotechnology investors may analyze each financial statement separately, they are all interrelated. For example, changes in Igene Biotechnology's assets and liabilities are reflected in the revenues and expenses on Igene Biotechnology's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Igene Biotechnology. Please read more on our technical analysis and fundamental analysis pages.
Igene Biotechnology, Inc. focuses on the research, development, production, and commercialization of specialty ingredients for human and animal nutrition. IGENE Biotechnology, Inc. was founded in 1981 and is based in Columbia, Maryland. IGENE BIOTECHNOLOGY operates under Agricultural Inputs classification in the United States and is traded on PNK Exchange. It employs 18 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Igene Pink Sheet
Igene Biotechnology financial ratios help investors to determine whether Igene Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Igene with respect to the benefits of owning Igene Biotechnology security.